Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".

Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". Circulation. 2020 Sep 08;142(10):e129-e130 Authors: Zelniker TA, Raz I, Sabatine MS, Wiviott SD PMID: 32897752 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32897752?dopt=Abstract

Source: Circulation - September 7, 2020 Category: Cardiology Authors: Zelniker TA, Raz I, Sabatine MS, Wiviott SD Tags: Circulation Source Type: research